Japan news from FierceBiotech
News
Takeda gains RNAi tech with $1B Alnylam deal
Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. The deal Read more...
Astellas faces new delay for Advagraf approval
Japan's Astellas Pharma has run into a new roadblock in its pursuit of regulatory approval of Advagraf, its second generation version of the blockbuster transplant drug Prograf. The FDA has raised Read more...
Arana gains development partner for cancer program
Australia's Arana Therapeutics has struck a deal to co-develop an experimental colorectal cancer therapy with Japan's Kyowa Hakko Kogyo. Arana will receive up to $8 million in the joint venture and Read more...
Pfizer lands schizophrenia drug in $22M deal
Japan's Taisho has granted all commercial rights to its preclinical schizophrenia drug outside of Japan to Pfizer for $22 million up front. TS-032 is an mGluR agonist, which promises to influence the Read more...
Eisai expands U.S. ops with $3.9B MGI buyout
A little over a week after announcing that it would explore its "strategic alternatives," MGI Pharma Read more...
Astellas inks $537M deal for Agensys
Japan's Astellas has forged a deal to buy Santa Monica, CA-based Read more...
AEterna gets its ducks in a row
Executives at AEterna Zentaris have taken a good, long look at the company's pipeline and operations and have identified a number of changes that will take place. Cetrorelix, currently in a Phase Read more...
ALSO NOTED: GSK to commercialize Lunesta; second headline; and much more...
> GlaxoSmithKline has signed on to commercialize Sepracor's insomnia drug Lunesta, agreeing to pay $20 million up front and up to $155 million in total for milestones and licensing fees. Glaxo Read more...
ALSO NOTED: MonoSol Rx sets IPO; Entelos buys Iconix; and much more...
> MonoSol Rx has set the terms on an IPO of four million shares. The offering is expected to raise up to $70 million if its hits its range of $16 to $18 a share. Read more...
ALSO NOTED: Indevus gains $50M payday; Genzyme settles suit; AnGes submits ERT; and much more...
> Indevus has snared a $49.9 million milestone payment following the FDA's approval of Sanctura XR. Read more...
Get more Japan coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends